AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Popularity #2,205Earnings are out

ANAB · NASDAQ · Biotechnology

AnaptysBio (ANAB)

Manages Jemperli and imsidolimab royalties through GSK and Vanda partnerships.

$51.42

vs last close−2.51 (−4.65%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	3	9	7	11	30	43	28	22	76	108	26	27
Cost of revenue	31	34	37	42	42	43	41	38	31	−108	1	0
Gross profit	−28	−25	−30	−31	−12	1	−13	−16	45	216	25	0
	10	18	12	9	11	10	14	11	10	149	60	19
Research & development	31	41	37	42	42	43	41	38	31	26	34	3
	10	10	12	9	11	10	14	11	10	16	26	16
General & administrative	10	10	12	9	11	10	14	11	10	16	26	16
Other expenses	−31	−34	−37	−42	−42	−43	−41	−38	−31	108	0	0
Operating income	−38	−42	−42	−40	−23	−10	−28	−26	35	67	−35	14
	0	0	−2	−6	−10	−12	−12	−12	−20	−17	−18	−18
Interest income	5	5	5	5	5	5	4	4	3	3	3	1
Interest expense	4	5	6	11	15	17	18	20	23	20	21	−20
Other non-operating income	−5	−7	−5	−5	−5	−5	−6	−7	−3	−3	−3	0
Income before tax	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53	−4
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	181
Net income from continuing operations	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53	184
Net income	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53	184
EPS, basic	−$1.41	−$1.57	−$1.64	−$1.71	−$1.14	−$0.77	−$1.28	−$1.34	$0.52	$1.79	−$1.84	$6.28
EPS, diluted	−$1.41	−$1.57	−$1.64	−$1.71	−$1.14	−$0.77	−$1.28	−$1.34	$0.52	$1.58	−$1.84	$5.11
Weighted average shares, basic	27	27	27	27	29	30	31	29	29	28	29	29
Weighted average shares, diluted	27	27	27	27	29	30	31	29	29	31	29	36
EBITDA	−32	−35	−37	−35	−17	−4	−21	−18	38	70	−31	14
Depreciation & amortization	1	0	1	1	1	1	1	1	1	1	1	0
EBIT	−33	−35	−38	−36	−17	−4	−21	−19	38	69	−32	0